South Korean donor skin injection Elravie Re2O sparks regulatory and ethical debate

South Korea's aesthetic market is adopting Elravie Re2O, an anti-aging injection derived from the acellular dermal matrix of deceased human donors, creating a regulatory gap that leaves clinicians navigating unvetted safety profiles. Because the South Korean Ministry of Food and Drug Safety classifies this collagen and elastin treatment as human tissue under the Human Tissue Safety Management Act, manufacturer L&C Bio avoids the clinical trials and safety approvals required for competitors like salmon-derived Rejuran or synthetic Juvelook. This regulatory classification has triggered ethical protests in South Korea, where civic groups argue that diverting donated skin from reconstructive burn surgeries to elective aesthetic clinics undermines the public donation system. The treatment is not approved by the United States Food and Drug Administration. For clinical business owners tracking global device pipelines, the controversy underscores the volatile legal and ethical landscape of donor-derived biomaterials. Expect tight domestic regulatory scrutiny and potential patient pushback on sourcing if similar human-tissue therapies attempt to enter the US market.

Source: Dimsum Daily, https://www.dimsumdaily.hk/controversial-human-skin-injection-for-anti-ageing-gains-rapid-popularity-in-south-koreas-beauty-market/